Skip to main content

Table 1 Breast cancer screening outcome in postmenopausal women for users of HRT compared to never users

From: Hormone replacement therapy and false positive recall in the Million Women Study: patterns of use, hormonal constituents and consistency of effect

  Total women screened (n = 87967a) Women recalled to assessment Adjusted RR (95% CI) of false positive recallb Heterogeneity/trend, p-value
   No breast cancer (false positive recall) Screen-detected breast cancer   
   % n % n   
Total 87,967 3.0 2,629 0.5 399   
Never used HRTc 44,620 2.4 1,057 0.4 193 1.00 χ2 1 (heterogeneity) = 90.1,
Ever used HRT 43,332 3.6 1,572 0.5 206 1.47 (1.36–1.60) P < 0.001
Past user of HRT 13,829 2.8 382 0.3 48 1.21 (1.06–1.38)  
Time since last use (median)        χ2 1 (trend) = 14.0, p < 0.001
   Current user (0 years) 28,788 4.0 1,157 0.5 154 1.64 (1.50–1.80)  
   <1 year since last use (0.5 years) 1,764 3.6 63 0.3 6 1.42 (1.08–1.86)  
   1–4 years since last use (2 years) 5,931 3.0 176 0.4 21 1.23 (1.04–1.46)  
   ≥5 years since last use (7 years) 3,813 2.4 92 0.3 13 1.07 (0.85–1.34)  
Duration of use among current users of HRT (median)        χ2 1 (trend) = 2.1, p = 0.2
   <1 year (0.5 years) 1,935 3.9 75 0.3 5 1.41 (1.10–1.81)  
   1–4 years (3 years) 9,790 4.2 410 0.6 54 1.58 (1.40–1.79)  
   5–9 years (6 years) 11,280 3.9 441 0.6 71 1.74 (1.53–1.97)  
   ≥10 years (11 years) 4,963 3.9 193 0.4 21 1.74 (1.46–2.06)  
Duration of use among past users of HRT (median)        χ2 1 (trend) = 8.4, p = 0.004
   <1 year (0.5 years) 4,014 2.4 95 0.3 13 0.95 (0.77–1.18)  
   1–4 years (3 years) 5,152 2.8 143 0.3 17 1.29 (1.07–1.56)  
   ≥5 years (8 years) 3,061 3.4 104 0.5 14 1.54 (1.23–1.93)  
  1. aNumbers do not always add up to total due to missing values. bStratified by screening centre, age, time since menopause, previous screening, body mass index and previous breast operation. cReference group. CI, confidence interval; HRT, hormone replacement therapy; RR, relative risk.